GREAT READ from another AVNR poster
Forget $500 million and think more like $5B
Board, I haven’t posted here for so long that I can’t remember. However, I got into AVNR in the 90s; I’ve been to 7 annual stockholders’ meetings over the years (none lately). So in reading everyone’s posts on what the value of the company’s revenue stream might be, I have to share a few things. You who say we have a shooting star are right on, imho. What has been pointed out so far is generally short of the true potential in this one drug.
From a March 9, 2005 AVNR PR: “AVANIR, through its subsidiary, holds the exclusive worldwide marketing rights to Neurodex for five indications under a royalty-bearing license with the owner of the underlying technology, The Center for Neurologic Study”
Here are the five indications:
pseudobulbar affect (from many diseases)
Nueropathic Pain (diabetic is one big market for this but not the only)
Fibromyalgia (think how big this one might be)
Chronic cough
Addiction therapy
These are all related because dextromethorphan works on that part of the brain that all of these issues stem from.
During the middle of the previous decade, some of us calculated that these indications may well be worth $5B annual revenue from the US alone. With the broad ranging approval we have, this could happen in shorter time frames than many imagine. Then add in Europe and the rest of the world……….
I’m not going to predict a share price but reading JJKing’s post on “how stocks work,” and his and others posts on what they think the pps could be, I believe it won’t take long. ( $30 - $40 pps )
